#1 Clinical Trials Search in Europe

Obeticholic Acid

Obeticholic acid (OCA) is an emerging drug being studied in clinical trials for various liver and metabolic disorders. This article summarizes key findings from recent trials investigating OCA’s effects on conditions like primary biliary cholangitis, nonalcoholic fatty liver disease, and bile acid diarrhea. We’ll explore how this farnesoid X receptor agonist may impact liver function, cholesterol metabolism, and other health markers in patients with these challenging conditions.

Table of Contents

What is Obeticholic Acid?

Obeticholic Acid (OCA) is a medication that has been developed to treat various liver conditions. It’s also known by other names such as INT-747, 6α-Ethyl chenodeoxycholic acid (6-ECDCA), and is marketed under the brand name Ocaliva[1][2]. OCA is a semi-synthetic bile acid, which means it’s a modified version of a natural substance found in our bodies[3].

How Does It Work?

Obeticholic Acid works by activating a specific protein in our body called the Farnesoid X Receptor (FXR). This protein plays a crucial role in regulating bile acids, fats, and sugar in our body. When OCA activates FXR, it can help improve various aspects of liver function and metabolism[4].

Specifically, OCA can:

  • Reduce the production of bile acids, which can be harmful in excess
  • Improve the flow of bile from the liver
  • Help regulate fat and sugar metabolism in the liver
  • Potentially reduce inflammation and scarring in the liver

Conditions Treated

Obeticholic Acid is being studied and used for several liver-related conditions:

  1. Primary Biliary Cholangitis (PBC): This is a chronic liver disease where the bile ducts in the liver are slowly destroyed. OCA has been approved for use in PBC patients who don’t respond well to the standard treatment[5].
  2. Non-alcoholic Steatohepatitis (NASH): This is a type of fatty liver disease not caused by alcohol. OCA has shown promise in improving liver health in NASH patients[6].
  3. Non-alcoholic Fatty Liver Disease (NAFLD): This is a broader category that includes NASH. Studies are ongoing to see if OCA can help patients with NAFLD[6].
  4. Bile Acid Diarrhea: Some research is looking at whether OCA can help patients who have diarrhea caused by bile acid problems[2].

Dosage and Administration

Obeticholic Acid is typically taken as a tablet by mouth. The dosage can vary depending on the condition being treated and the individual patient. In most studies, doses ranged from 10 mg to 25 mg per day[1][2][6]. However, it’s crucial to follow your doctor’s instructions regarding dosage and administration.

Potential Benefits

Research has shown that Obeticholic Acid may offer several benefits:

  • Improved liver function tests: OCA has been shown to reduce levels of certain enzymes that indicate liver damage[6].
  • Reduced liver fat: In patients with fatty liver diseases, OCA may help decrease the amount of fat in the liver[6].
  • Improved bile flow: For conditions like PBC, OCA can help improve the flow of bile from the liver[5].
  • Potential reduction in liver scarring: Some studies suggest OCA might help reduce fibrosis (scarring) in the liver[6].

Side Effects

Like all medications, Obeticholic Acid can cause side effects. Some of the reported side effects include:

  • Itching (pruritus): This is the most common side effect[5].
  • Changes in cholesterol levels: OCA may affect cholesterol levels, particularly increasing LDL (“bad”) cholesterol[7].
  • Fatigue
  • Abdominal pain or discomfort
  • Constipation

It’s important to discuss any side effects with your healthcare provider.

Ongoing Research

Obeticholic Acid is still being studied for various conditions and effects. Some areas of ongoing research include:

  • Effects on gut microbiota (the bacteria in our intestines)[1]
  • Impact on gastric motility (how food moves through the stomach and intestines)[8]
  • Potential use in obesity and gallstone disease[9]
  • Long-term effects and safety in various liver conditions[10]

As research continues, we may learn more about how Obeticholic Acid can be used to treat liver and metabolic diseases.

Aspect Details
Drug Name Obeticholic Acid (OCA)
Mechanism Farnesoid X Receptor (FXR) agonist
Main Conditions Studied Primary Biliary Cholangitis (PBC), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH), Bile Acid Diarrhea, Lipodystrophy
Key Findings – Improved liver enzyme levels in PBC patients – Reduced liver fat content in NAFLD/NASH – Potential improvements in cholesterol metabolism – Possible benefits in bile acid diarrhea and lipodystrophy
Common Dosage in Trials 10-25 mg daily
Notable Side Effects Pruritus (itching), changes in cholesterol levels
Current Approval Status Approved for PBC; investigational for other conditions
Ongoing Research Focus Long-term efficacy and safety, optimal dosing, combination therapies

FAQ

  • What is obeticholic acid and how does it work? Obeticholic acid is a semi-synthetic bile acid that acts as a potent agonist of the farnesoid X receptor (FXR). It works by activating FXR, which regulates bile acid synthesis, transport, and other aspects of lipid and glucose metabolism. This mechanism allows OCA to potentially improve liver function and metabolic health.
  • What conditions is obeticholic acid being studied for in clinical trials? Clinical trials are investigating obeticholic acid for several conditions, including primary biliary cholangitis (PBC), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), bile acid diarrhea, and lipodystrophy. These trials aim to assess its efficacy in improving liver health, cholesterol levels, and other metabolic markers.
  • What are some potential benefits of obeticholic acid seen in trials? Some potential benefits observed in trials include improvements in liver enzyme levels, reductions in liver fat content, improvements in cholesterol profiles, and potential slowing of liver disease progression in conditions like PBC and NASH. However, more research is needed to fully establish its long-term efficacy and safety.
  • Are there any side effects associated with obeticholic acid? Common side effects reported in trials include pruritus (itching) and changes in cholesterol levels. Some studies have noted increases in LDL cholesterol, which requires monitoring. As with any medication in clinical trials, the full safety profile is still being established through ongoing research.
  • Is obeticholic acid currently approved for use in any conditions? Obeticholic acid (brand name Ocaliva) is approved for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. Its use in other conditions is still investigational and not yet approved.

Ongoing Clinical Trials on Obeticholic Acid

  • Study on Obeticholic Acid for Children with Biliary Atresia After Kasai Procedure

    Not yet recruiting

    1 1
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +1

  • Study on the Long-Term Safety of Obeticholic Acid and Bezafibrate for Patients with Primary Biliary Cholangitis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Croatia Czechia Estonia France Germany +6

  • Study on the Effects of Bezafibrate and Obeticholic Acid for Patients with Primary Biliary Cholangitis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Effects of Obeticholic Acid and Bezafibrate for Patients with Primary Biliary Cholangitis Who Cannot Tolerate Ursodeoxycholic Acid

    Not recruiting

    1 1
    Investigated drugs:
    Belgium Croatia Czechia Estonia France Germany +6

Glossary

  • Obeticholic Acid (OCA): A semi-synthetic bile acid and potent agonist of the farnesoid X receptor (FXR), being studied for various liver and metabolic disorders.
  • Farnesoid X Receptor (FXR): A nuclear receptor that plays a key role in regulating bile acid synthesis, lipid metabolism, and glucose homeostasis.
  • Primary Biliary Cholangitis (PBC): A chronic autoimmune liver disease characterized by progressive destruction of the bile ducts, leading to cholestasis and potential cirrhosis.
  • Nonalcoholic Fatty Liver Disease (NAFLD): A condition characterized by excessive fat accumulation in the liver of people who drink little or no alcohol.
  • Nonalcoholic Steatohepatitis (NASH): An advanced form of NAFLD characterized by liver inflammation and damage, which can progress to cirrhosis.
  • Bile Acid Diarrhea: A condition where excess bile acids in the colon lead to chronic watery diarrhea.
  • Lipodystrophy: A group of disorders characterized by abnormal fat distribution in the body, often associated with metabolic complications.
  • Ursodeoxycholic Acid (UDCA): A naturally occurring bile acid used as a standard treatment for primary biliary cholangitis.
  • Alkaline Phosphatase (ALP): A liver enzyme often elevated in cholestatic liver diseases like PBC, used as a marker of disease activity and treatment response.
  • Fibroblast Growth Factor 19 (FGF19): A hormone produced in the intestine that regulates bile acid synthesis and is stimulated by FXR activation.

References

  1. https://clinicaltrials.gov/study/NCT02532335
  2. https://clinicaltrials.gov/study/NCT01585025
  3. https://clinicaltrials.gov/study/NCT04076527
  4. https://clinicaltrials.gov/study/NCT03836937
  5. https://clinicaltrials.gov/study/NCT03253276
  6. https://clinicaltrials.gov/study/NCT01265498
  7. https://clinicaltrials.gov/study/NCT01865812
  8. https://clinicaltrials.gov/study/NCT05740631
  9. https://clinicaltrials.gov/study/NCT01625026
  10. https://clinicaltrials.gov/study/NCT02430077